DrugPatentWatch Database Preview
Details for Patent: 9,198,925
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which drugs does patent 9,198,925 protect, and when does it expire?
Patent 9,198,925 protects BYDUREON, BYDUREON PEN, BYDUREON BCISE, QTERNMET XR, XIGDUO XR, FARXIGA, and QTERN, and is included in six NDAs.
This patent has thirty-four patent family members in fifteen countries.
Summary for Patent: 9,198,925
Title: | Pharmaceutical formulations containing an SGLT2 inhibitor |
Abstract: | Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate ##STR00001## and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release. |
Inventor(s): | Bindra; Dilbir S. (New Brunswick, NJ), Dali; Mandar V. (Bridgewater, NJ), Parab; Prakash V. (New Brunswick, NJ), Patel; Jatin M. (New Brunswick, NJ), Tao; Li (New Brunswick, NJ), Tejwani; Ravindra W. (Monmouth Junction, NJ), Vatsaraj; Nipa (New Brunswick, NJ), Wu; Yongmei (New Brunswick, NJ) |
Assignee: | AstraZeneca AB (Sodertalje, SE) |
Application Number: | 14/267,984 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 9,198,925
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Ab | BYDUREON | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-001 | Jan 27, 2012 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF TYPE 2 DIABETES MELLITUS | Start Trial | ||||
Astrazeneca Ab | BYDUREON | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-001 | Jan 27, 2012 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE | Start Trial | ||||
Astrazeneca Ab | BYDUREON PEN | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-002 | Feb 28, 2014 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE | Start Trial | ||||
Astrazeneca Ab | BYDUREON PEN | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-002 | Feb 28, 2014 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF TYPE 2 DIABETES MELLITUS | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,198,925
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 065809 | Start Trial | |||
Australia | 2008228714 | Start Trial | |||
Brazil | 122017015098 | Start Trial | |||
Brazil | PI0809233 | Start Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |